Navigation Links
Verathon Inc. Launches Enhanced BladderScan(R) Bladder Volume Instrument With Small Child Mode
Date:3/11/2008

BOTHELL, Wash., March 11 /PRNewswire/ -- Verathon(R) is pleased to announce a new Small Child Mode for the portable BladderScan(R) BVI 9400 bladder volume instrument with patent-pending NeuralHarmonics(TM) Technology. Small Child Mode enables health care providers to measure bladder volume noninvasively on children weighing less than 60 pounds and standing less than 48 inches high with the same instrument used for adult patients. This enhanced BladderScan(R) BVI 9400 will make its official debut at the Association of Peri-Operative Registered Nurses (AORN) conference in Anaheim, CA on April 1. (Verathon Booth #785)

(Logo: http://www.newscom.com/cgi-bin/prnh/20061011/SFW044LOGO)

BladderScan(R) portable ultrasound instruments, the gold standard in bladder volume measurement, help diagnose urinary retention, evaluate common urological conditions and prevent unnecessary catheterization.

The newest BladderScan(R) in the line, the BVI 9400, now with Small Child Mode, allows Urologists, Primary Care physicians and Acute Care facilities to standardize on one bladder volume instrument for all patient age groups. The BladderScan(R) BVI 9400 also incorporates NeuralHarmonics(TM) Technology. This patent-pending advance in the science of ultrasound helps improve both speed and accuracy in bladder volume measurement. NeuralHarmonics(TM) Technology helps achieve previously unattainable differentiation of the bladder, urine and hypo-echogenic regions such as the uterus, thereby reducing error and minimizing uncertainty in measurements of bladder function.

"The new BVI 9400 with Small Child Mode and NeuralHarmonics(TM) Technology offers health care providers a comprehensive bladder volume instrument for their practice or facility," said Gerald McMorrow, CEO, Founder and Chairman of the Board of Verathon, Inc. "The BVI 9400 not only measures bladder function for pati
'/>"/>

SOURCE Verathon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Aircraft Medical Files Counter Action Against Verathon
2. Verathon Inc., maker of GlideScope(R) Video Laryngoscopes, Introduces Free Grant Writing Kit for EMS Professionals
3. European Patent Office Upholds Verathons IP Against Aircraft Medical Challenge
4. Verathon Inc., Maker of BladderScan(R) and GlideScope(R), Ranks in Deloittes 2007 Washington State Technology Fast 50 for 4th Time in Past 6 Years
5. Verathon Inc. Introduces GlideScope(R) Ranger Single Use Video Laryngoscope for Emergency Departments, EMS and Military; Enables Fast Intubations and Eliminates Time-Consuming Disinfection
6. Smart Circle International, LLC Launches Its National Health and Wellness Network Complimentary 1/2-Hour Massage for Everyone
7. WaferGen Launches SmartSlide 200 Micro-Incubation System for Stem Cell Research and Cell Biology Applications
8. Student Pugwash USA launches science policy election guide for young voters
9. Compuware Launches Strategic IT Service Management Initiative for Healthcare Industry
10. Shire Launches Patient Education Forums on Better Managing the Challenges of Ulcerative Colitis
11. Raintree Systems Launches the First Integrated Practice Management and Electronic Medical Records Application Within the Bariatric Surgery Industry
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting 2New FDA Approved Breast Cancer Screening Tool 2New FDA Approved Breast Cancer Screening Tool 3KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 1KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 2KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 3KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 4KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 5KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 6Merrimack Pharmaceuticals Names Clet Niyikiza Ph D Senior Vice President Development 14175 1Merrimack Pharmaceuticals Names Clet Niyikiza Ph D Senior Vice President Development 14175 2Alzheimers Soars Global Focus Needed 3A Study 57748 1Alzheimers Soars Global Focus Needed 3A Study 57748 2Alzheimers Soars Global Focus Needed 3A Study 57748 3
Other Medicine Technology:Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 2Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 3Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 4Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 5Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 6Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 2Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 3Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 4Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 5Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 6Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 7Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 8Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 9Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 10